"Pfizer will be the leading antibacterial drug manufacturer in 2012, with revenue of $3.23bn" says visiongain report

A new report by visiongain predicts that Pfizer will retain its position as the global leader in the antibacterial drugs market in 2012. In that year, its seven leading antibiotics will achieve $3.23bn in revenue. However, patent expiries will cause Pfizer to lose antibacterial revenue between 2011 and 2016, as its market share falls to 6.7%. Those findings appear in Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022, published in June 2012.

Visiongain’s analysis indicates that, in 2011, the top 20 antibacterial drug manufacturers accounted for 37.8% of that market. As well as Pfizer, other leading companies included Big Pharma players such as GSK, AstraZeneca and J&J, as well as acute care specialists, including Cubist Pharmaceuticals and ViroPharma. Many companies will experience falling market share in the coming 10 years, though. Patent expiries, generic competition and a relative lack of pipeline therapies will drive this decline.

Richard Lang, a pharmaceutical industry analyst in visiongain, said: “The antibacterial drugs market is highly fragmented and even many of the leading players rely on off-patent products for portions of their antibacterial revenue. Leading companies likely to see their market share grow in the future are those still taking an active interest in antibacterial drug development. Companies that have signed licensing deals for new products will also benefit.”

In 2017, the leading antibacterial drug, in terms of revenue, will be Cubist’s Cubicin (daptomycin). Revenue is forecast to grow strongly in the first half of the decade. Besides Cubist, other companies will benefit from this growth, including Novartis and Merck & Co., who both market the drug in certain territories. Companies with similar licensing deals for Optimer Pharmaceuticals’ C. difficile infection treatment, Dificid (fidaxomicin), will also benefit from rapid revenue growth. The C. difficile treatment market will become more crowded from 2012 to 2022, though, with a number of leading players targeting this submarket with pipeline drugs.

Visiongain’s report provides revenue forecasts to 2022 for the leading 20 companies in the antibacterial drugs sector. For each company, the report also contains:

• 2011 revenue analysis
• A SWOT (strengths, weaknesses, opportunities and threats) analysis for the antibacterials division
• Antibacterial R&D pipeline analysis.

Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022 adds to visiongain’s range of Pharma Leader Series reports, assessing the prospects of leading companies in important pharmaceutical sectors. Visiongain is a business information provider based in London, UK.

For sample pages and further information concerning the visiongain report Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022 please visit: http://www.visiongain.com/Report/841/Pharma-Leader-Series-Top-20-Antibacterial-Drug-Manufacturers-2012-2022

For an executive summary of this report or to order it today please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Visiongain
BSG House
226-236 City Road
London EC1V 2QY
United Kingdom

This release was published on openPR.